RAPT Therapeutics, Inc.
RAPT
$11.32
$0.5955.55%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 7.20M | 7.22M | 8.01M | 6.45M | 6.69M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 19.54M | 19.27M | 54.47M | 19.79M | 29.33M |
Operating Income | -19.54M | -19.27M | -54.47M | -19.79M | -29.33M |
Income Before Tax | -17.64M | -17.17M | -53.25M | -18.43M | -27.66M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -17.64M | -17.17M | -53.25M | -18.43M | -27.66M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -17.64M | -17.17M | -53.25M | -18.43M | -27.66M |
EBIT | -19.54M | -19.27M | -54.47M | -19.79M | -29.33M |
EBITDA | -19.31M | -19.01M | -54.18M | -19.49M | -29.03M |
EPS Basic | -0.65 | -0.64 | -9.12 | -3.79 | -5.69 |
Normalized Basic EPS | -0.41 | -0.41 | -5.76 | -2.37 | -3.56 |
EPS Diluted | -0.65 | -0.64 | -9.12 | -3.79 | -5.69 |
Normalized Diluted EPS | -0.41 | -0.41 | -5.76 | -2.37 | -3.56 |
Average Basic Shares Outstanding | 26.95M | 26.93M | 5.84M | 4.86M | 4.86M |
Average Diluted Shares Outstanding | 26.95M | 26.93M | 5.84M | 4.86M | 4.86M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |